AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (905.5 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

Oncolytic adenoviruses: A thorny path to glioma cure

Swedish Medical Center, Center for Advanced Brain Tumor Treatment, 550 17th Avenue, James Tower, Suite 570, Seattle, WA 98122, USA
Institute of Oral Health Research, University of Alabama at Birmingham School of Dentistry, 1919 7th Ave South, Birmingham, AL, 35294, USA
Michigan State University College of Medicine, Grand Rapids, MI, 49503, USA
Institute of Experimental Diagnostic and Biotherapy, N.N. Blokhin Cancer Research Center (RONC), Moscow 115478, Russia

Peer review under responsibility of Chongqing Medical University.

e Present addresses for Dr. Borovjagin AV: Department of Pathology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294, USA.

Show Author Information

Abstract

Glioblastoma Multiforme (GBM) is a rapidly progressing brain tumor. Despite the relatively low percentage of cancer patients with glioma diagnoses, recent statistics indicate that the number of glioma patients may have increased over the past decade. Current therapeutic options for glioma patients include tumor resection, chemotherapy, and concomitant radiation therapy with an average survival of approximately 16 months. The rapid progression of gliomas has spurred the development of novel treatment options, such as cancer gene therapy and oncolytic virotherapy. Preclinical testing of oncolytic adenoviruses using glioma models revealed both positive and negative sides of the virotherapy approach. Here we present a detailed overview of the glioma virotherapy field and discuss auxiliary therapeutic strategies with the potential for augmenting clinical efficacy of GBM virotherapy treatment.

Keywords

Brain tumorStem cellsGliomaAdenovirusSelf-replicated vector

References

1

Zouaoui S, Darlix A, Fabbro-Peray P, et al. Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurg Rev. 2014;37:415-424.
Crossref Google Scholar
2

Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012;14:819-829.
Crossref Google Scholar
3

Sant M, Minicozzi P, Lagorio S, Borge Johannesen T, Marcos-Gragera R, Francisci S. Survival of European patients with central nervous system tumors. Int J Cancer. 2012;131:173-185.
Crossref Google Scholar
4

Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
Crossref Google Scholar
5

Rich JN. Cancer stem cells in radiation resistance. Cancer Res. 2007;67:8980-8984.
Crossref Google Scholar
6

Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1:353-355.
Crossref Google Scholar
7

Friedman GK, Cassady KA, Beierle EA, Markert JM, Gillespie GY. Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res. 2012;71(4 Pt 2):500-510.
Crossref Google Scholar
8

Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell. 2007;1:607-611.
Crossref Google Scholar
9

Price RL, Song J, Bingmer K, et al. Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res. 2013;73:3441-3450.
Crossref Google Scholar
10

Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74:3466-3476.
Crossref Google Scholar
11

Cobbs CS. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol. 2013;25:682-688.
Crossref Google Scholar
12

Thaci B, Ulasov IV, Ahmed AU, Ferguson SD, Han Y, Lesniak MS. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Gene Ther. 2013;20:318-327.
Crossref Google Scholar
13

Weiler M, Blaes J, Pusch S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014;111:409-414.
Crossref Google Scholar
14

Grzmil M, Hemmings BA. Overcoming resistance to rapalogs in gliomas by combinatory therapies. Biochim Biophys Acta. 2013;1834:1371-1380.
Crossref Google Scholar
15

Rowe WP, Hartley JW, Roizman B, Levy HB. Characterization of a factor formed in the course of adenovirus infection of tissue cultures causing detachment of cells from glass. J Exp Med. 1958;108:713-729.
Crossref Google Scholar
16

Levy HB, Rowe WP, Snellbaker FL, Hartley JW. Biochemical changes in HeLa cells associated with infection by type 2 adenovirus. Proc Soc Exp Biol Med. 1957;96:732-738.
Crossref Google Scholar
17

Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques. 2008;45:659-662 664-658.
Crossref Google Scholar
18

Kim YH, Lachuer J, Mittelbronn M, et al. Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol. 2011;21:645-651.
Crossref Google Scholar
19

Nakamura M, Konishi N, Tsunoda S, et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer. 1997;80:242-249.
Crossref Google Scholar
20

Jha P, Suri V, Singh G, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol. 2011;20:225-232.
Crossref Google Scholar
21

Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5:965-976.
Crossref Google Scholar
22

Libertini S, Iacuzzo I, Ferraro A, et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology. 2007;148:5186-5194.
Crossref Google Scholar
23

Geoerger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 2002;62:764-772.
Google Scholar
24

Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639-645.
Crossref Google Scholar
25

Libertini S, Abagnale A, Passaro C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer. 2011;18:129-141.
Crossref Google Scholar
26

Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2-12.
Crossref Google Scholar
27

Gomez-Manzano C, Balague C, Alemany R, et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene. 2004;23:1821-1828.
Crossref Google Scholar
28

Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther. 2013;20:1131-1139.
Crossref Google Scholar
29

Fuxe J, Liu L, Malin S, Philipson L, Collins VP, Pettersson RF. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer. 2003;103:723-729.
Crossref Google Scholar
30

Nandi S, Ulasov IV, Rolle CE, Han Y, Lesniak MS. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J Gene Med. 2009;11:1005-1011.
Crossref Google Scholar
31

Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 2007;67:8783-8790.
Crossref Google Scholar
32

Li X, Mao Q, Wang D, Zhang W, Xia H. A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy. Hum Gene Ther. 2012;23:589-596.
Crossref Google Scholar
33

Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med. 2007;9:151-160.
Crossref Google Scholar
34

Ulasov IV, Zhu ZB, Tyler MA, et al. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007;18:589-602.
Crossref Google Scholar
35

Yokoyama T, Iwado E, Kondo Y, et al. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther. 2008;15:1233-1239.
Crossref Google Scholar
36

Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002;62:5736-5742.
Google Scholar
37

de Jonge J, Berghauser Pont LM, Idema S, et al. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma. J Gene Med. 2013;15:134-141.
Crossref Google Scholar
38

Holzmuller R, Mantwill K, Haczek C, et al. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer. 2011;129:1265-1276.
Crossref Google Scholar
39

Alonso MM, Jiang H, Yokoyama T, et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther. 2008;16:487-493.
Crossref Google Scholar
40

Lamfers ML, Idema S, Bosscher L, et al. Differential effects of combined Ad5-delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res. 2007;13:7451-7458.
Crossref Google Scholar
41

Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007;99:1410-1414.
Crossref Google Scholar
42

Alonso MM, Cascallo M, Gomez-Manzano C, et al. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res. 2007;67:8255-8263.
Crossref Google Scholar
43

Wickham TJ, Tzeng E, Shears 2nd LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 1997;71:8221-8229.
Crossref Google Scholar
44

Tyler MA, Ulasov IV, Borovjagin A, et al. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol Cancer Ther. 2006;5:2408-2416.
Crossref Google Scholar
45

Arwert E, Hingtgen S, Figueiredo JL, et al. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res. 2007;67:7335-7342.
Crossref Google Scholar
46

Grill J, Van Beusechem VW, Van Der Valk P, et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res. 2001;7:641-650.
Google Scholar
47

van Beusechem VW, Grill J, Mastenbroek DC, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol. 2002;76:2753-2762.
Crossref Google Scholar
48

van Beusechem VW, Mastenbroek DC, van den Doel PB, et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther. 2003;10:1982-1991.
Crossref Google Scholar
49

Lorimer IA, Lavictoire SJ. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe. J Immunol Methods. 2000;237:147-157.
Crossref Google Scholar
50

Piao Y, Jiang H, Alemany R, et al. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther. 2009;16:256-265.
Crossref Google Scholar
51

Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70.
Crossref Google Scholar
52

Ulasov IV, Rivera AA, Sonabend AM, et al. Comparative evaluation of survivin, midkine and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol Ther. 2007;6:679-685.
Crossref Google Scholar
53

Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell. 2006;17:1483-1493.
Crossref Google Scholar
54

Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol. 2009;34:729-742.
Crossref Google Scholar
55

Nandi S, Ulasov IV, Tyler MA, et al. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res. 2008;68:5778-5784.
Crossref Google Scholar
56

Muramatsu T. Midkine: a promising molecule for drug development to treat diseases of the central nervous system. Curr Pharm Des. 2011;17:410-423.
Crossref Google Scholar
57

Kohno S, Nakagawa K, Hamada K, et al. Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncol Rep. 2004;12:73-78.
Crossref Google Scholar
58

Jafri AM, Sarina S, George PJ, Nizam IM. Presence of telomerase activity with undetectable p16 gene mutation in Malaysian patients with brain tumor. Med J Malaysia. 2004;59:480-485.
Google Scholar
59

Kheirollahi M, Mehrazin M, Kamalian N, Mohammadi-asl J, Mehdipour P. Telomerase activity in human brain tumors: astrocytoma and meningioma. Cell Mol Neurobiol. 2013;33:569-574.
Crossref Google Scholar
60

Bortolanza S, Qian C, Kramer MG, et al. An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. J Mol Med (Berl). 2005;83:736-747.
Crossref Google Scholar
61

Won J, Chang S, Oh S, Kim TK. Small-molecule-based identification of dynamic assembly of E2F-pocket protein-histone deacetylase complex for telomerase regulation in human cells. Proc Natl Acad Sci U S A. 2004;101:11328-11333.
Crossref Google Scholar
62

Hoffmann D, Meyer B, Wildner O. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med. 2007;9:764-778.
Crossref Google Scholar
63

Horst M, Brouwer E, Verwijnen S, et al. Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med. 2007;9:1071-1079.
Crossref Google Scholar
64

Zheng X, Rao XM, Snodgrass C, et al. Adenoviral E1a expression levels affect virus-selective replication in human cancer cells. Cancer Biol Ther. 2005;4:1255-1262.
Crossref Google Scholar
65

Irving J, Wang J, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther.. 2004;11(3):174-185.
Crossref Google Scholar
66

Harkins LE, Matlaf LA, Soroceanu L, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae. 2010;1:8.
Crossref Google Scholar
67

Taher C, de Boniface J, Mohammad AA, et al. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One. 2013;8:e56795.
Crossref Google Scholar
68

Ding D, Han S, Wang Z, Guo Z, Wu A. Does the existence of HCMV components predict poor prognosis in glioma?. J Neurooncol. 2014;116:515-522.
Crossref Google Scholar
69

Dos Santos CJ, Stangherlin LM, Figueiredo EG, Correa C, Teixeira MJ, da Silva MC. High prevalence of HCMV and viral load in tumor tissues and peripheral blood of glioblastoma multiforme patients. J Med Virol. 2014 Nov;86(11):1953-1961.
Crossref Google Scholar
70

Soroceanu L, Matlaf L, Bezrookove V, et al. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res. 2011;71:6643-6653.
Crossref Google Scholar
71

Hayakawa H, Uchiumi T, Fukuda T, et al. Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry. 2002;41:12739-12744.
Crossref Google Scholar
72

Izumi H, Imamura T, Nagatani G, et al. Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3′→5′ exonuclease activity. Nucleic Acids Res. 2001;29:1200-1207.
Crossref Google Scholar
73

Koike K, Uchiumi T, Ohga T, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997;417:390-394.
Crossref Google Scholar
74

Gaudreault I, Guay D, Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res. 2004;32:316-327.
Crossref Google Scholar
75

Bieler A, Mantwill K, Dravits T, et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther. 2006;17:55-70.
Crossref Google Scholar
76

Mantwill K, Naumann U, Seznec J, et al. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells. J Transl Med. 2013;11:216.
Crossref Google Scholar
77

Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 1996;56:150-153.
Google Scholar
78

Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997;3:1145-1149.
Crossref Google Scholar
79

Muller H, Moroni MC, Vigo E, Petersen BO, Bartek J, Helin K. Induction of S-phase entry by E2F transcription factors depends on their nuclear localization. Mol Cell Biol. 1997;17:5508-5520.
Crossref Google Scholar
80

Yao W, Guo G, Zhang Q, Fan L, Wu N, Bo Y. The application of multiple miRNA response elements enables oncolytic adenoviruses to possess specificity to glioma cells. Virology. 2014;458-459:69-82.
Crossref Google Scholar
81

Yamamoto M, Davydova J, Takayama K, Alemany R, Curiel DT. Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted. J Virol. 2003;77:1633-1637.
Crossref Google Scholar
82

Osborne TF, Berk AJ. Far upstream initiation sites for adenovirus early region 1A transcription are utilized after the onset of viral DNA replication. J Virol. 1983;45:594-599.
Crossref Google Scholar
83

Berk AJ. Adenovirus promoters and E1A transactivation. Annu Rev Genet. 1986;20:45-79.
Crossref Google Scholar
84

Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer. 2009;100:1154-1164.
Crossref Google Scholar
85

Tyler MA, Ulasov IV, Lesniak MS. Cancer cell death by design: apoptosis, autophagy and glioma virotherapy. Autophagy. 2009;5:856-857.
Crossref Google Scholar
86

Tazawa H, Kagawa S, Fujiwara T. Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Acta Med Okayama. 2013;67:333-342.
Google Scholar
87

Jiang H, White EJ, Rios-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol. 2011;85:4720-4729.
Crossref Google Scholar
88

Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther. 2010;12:530-537.
Google Scholar
89

Kim J, Kim PH, Yoo JY, et al. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Ther. 2009;16:1111-1121.
Crossref Google Scholar
90

Jiang H, White EJ, Gomez-Manzano C, Fueyo J. Adenovirus's last trick: you say lysis, we say autophagy. Autophagy. 2008;4:118-120.
Crossref Google Scholar
91

Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther. 2005;12:61-71.
Crossref Google Scholar
92

Kaliberova LN, Krendelchtchikova V, Harmon DK, et al. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther. 2009;16:794-805.
Crossref Google Scholar
93

Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22:8628-8633.
Crossref Google Scholar
94

El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066-1075.
Crossref Google Scholar
95

Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003;13:135-147.
Crossref Google Scholar
96

Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 2000;102:43-53.
Crossref Google Scholar
97

Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
Crossref Google Scholar
98

Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865-5877.
Crossref Google Scholar
99

Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000;102:1-4.
Crossref Google Scholar
100

Tsamis KI, Alexiou GA, Vartholomatos E, Kyritsis AP. Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. Cancer Invest. 2013;31:630-638.
Crossref Google Scholar
101

Conrad C, Miller CR, Ji Y, et al. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 2005;12:284-294.
Crossref Google Scholar
102

Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62:773-780.
Google Scholar
103

Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology. 1996;220:152-162.
Crossref Google Scholar
104

Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol. 1996;70:2296-2306.
Crossref Google Scholar
105

Bilbao R, Bustos M, Alzuguren P, et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther. 2000;7:1824-1832.
Crossref Google Scholar
106

Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3:1354-1361.
Crossref Google Scholar
107

Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010;7:150-161.
Crossref Google Scholar
108

Bar EE. Glioblastoma, cancer stem cells and hypoxia. Brain Pathol. 2011;21:119-129.
Crossref Google Scholar
109

Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012;1:322-332.
Crossref Google Scholar
110

Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009;15:501-513.
Crossref Google Scholar
111

Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene. 2003;22:2065-2072.
Crossref Google Scholar
112

Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013;21:1212-1223.
Crossref Google Scholar
113

Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther. 2008;16:1665-1673.
Crossref Google Scholar
114

Kleijn A, Kloezeman J, Treffers-Westerlaken E, et al. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One. 2014;9:e97495.
Crossref Google Scholar
115

Shinojima N, Hossain A, Takezaki T, et al. TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res. 2013;73:2333-2344.
Crossref Google Scholar
116

Hata N, Shinojima N, Gumin J, et al. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Neurosurgery. 2010;66:144-156 discussion 156–147.
Crossref Google Scholar
117

Birnbaum T, Roider J, Schankin CJ, et al. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol. 2007;83:241-247.
Crossref Google Scholar
118

Ahmed AU, Rolle CE, Tyler MA, et al. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther. 2010;18:1846-1856.
Crossref Google Scholar
119

Hai C, Jin YM, Jin WB, et al. Application of mesenchymal stem cells as a vehicle to deliver replication-competent adenovirus for treating malignant glioma. Chin J Cancer. 2012;31:233-240.
Crossref Google Scholar
120

Yong RL, Shinojima N, Fueyo J, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009;69:8932-8940.
Crossref Google Scholar
121

Tyler MA, Ulasov IV, Sonabend AM, et al. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther. 2009;16:262-278.
Crossref Google Scholar
122

Thaci B, Ahmed AU, Ulasov IV, et al. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther. 2012;19:431-442.
Crossref Google Scholar
123

Kim CK, Ahmed AU, Auffinger B, et al. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther. 2013;21:2063-2073.
Crossref Google Scholar
124

Ulasov IV, Tyler MA, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS. Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. J Med Virol. 2008;80:1595-1603.
Crossref Google Scholar
125

Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003;95:652-660.
Crossref Google Scholar
126

Kang YA, Shin HC, Yoo JY, Kim JH, Kim JS, Yun CO. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol Ther. 2008;16:1033-1040.
Crossref Google Scholar
127

Aboody KS, Najbauer J, Metz MZ, et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med. 2013;5(184), 184ra159.
Crossref Google Scholar
128

Belzile JP, Stark TJ, Yeo GW, Spector DH. Human cytomegalovirus infection of human embryonic stem cell-derived primitive neural stem cells is restricted at several steps but leads to the persistence of viral DNA. J Virol. 2014;88:4021-4039.
Crossref Google Scholar
129

Nakajima T, Mukai N. Cell origin of human adenovirus type 12-induced subcutaneous tumor in Syrian hamsters. Acta Neuropathol. 1979;45:187-194.
Crossref Google Scholar
130

Kirn D, Hermiston T. Induction of an oncogenic fusion protein by a viral gene – a new chapter in an old story. Nat Med. 1999;5:991-992.
Crossref Google Scholar
131

Mukai N, Kobayashi S. Undifferentiated intraperitoneal tumors induced by human adenovirus type 12 in hamsters. Am J Pathol. 1972;69:331-348.
Google Scholar
132

Hohlweg U, Hosel M, Dorn A, et al. Intraperitoneal dissemination of Ad12-induced undifferentiated neuroectodermal hamster tumors: de novo methylation and transcription patterns of integrated viral and of cellular genes. Virus Res. 2003;98:45-56.
Crossref Google Scholar
Genes & Diseases
Volume 1 Issue 2,
December 2014
Pages 214-226
DOI: 10.1016/j.gendis.2014.09.009
Cite this article:
Ulasov I, Borovjagin A, Schroeder B, et al. Oncolytic adenoviruses: A thorny path to glioma cure. Genes & Diseases, 2014, 1(2): 214-226. https://doi.org/10.1016/j.gendis.2014.09.009

295

Views

4

Downloads

14

Crossref

N/A

Web of Science

16

Scopus

0

CSCD

Altmetrics
Received: 08 September 2014
Accepted: 24 September 2014
Published: 13 October 2014
© 2014, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Return